Trial Summary
What is the purpose of this trial?
The number one preventable cause of death in the world is tobacco use. Cigarette smoking in particular, costs an estimated $300 billion due to expenses related to medical care and lost productivity. Despite similar smoking prevalence rates, blacks suffer disproportionately from smoking-related harms compared to whites.Sleep disparities such as shortened sleep duration, shorter circadian periodicity, earlier chronotype, and increased variability of sleep timing have been reported more frequently in blacks compared to whites. Given that poor sleep quality predicts relapse from smoking cessation programs, particularly among socioeconomically disadvantaged adults, sleep deficiencies and irregular timing of sleep may impact smoking craving and withdrawal symptoms over the course of the 24-hour day. Surprisingly, few studies have examined these temporal patterns of smoking and craving, and none with regard to sleep disruption, chronotype or racial disparities. A better understanding of these factors may explain heterogeneity within the smoking population, especially in minorities. Thus, the purpose of this proposal is to test the central hypothesis that the impact of chronotype and impaired sleep on cigarette usage as well as smoking dependence, urge/craving, and withdrawal depends on race.
Do I need to stop taking my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications, but if you are taking psychiatric medications, pain medications (like opioids), or sleep medications (such as Ambien, trazodone, melatonin, or CBD products), you cannot participate in Sub-study 3.
What data supports the idea that Sleep Management for Nicotine Addiction is an effective treatment?
The available research shows that addressing sleep problems can help improve smoking cessation outcomes. Sleep issues are common during nicotine withdrawal and can make quitting harder. By focusing on sleep, treatments like dual orexin receptor antagonists (DORAs) can reduce withdrawal symptoms and nicotine cravings, making it easier to quit smoking. This approach is promising because it targets both sleep and addiction, unlike other treatments that might worsen sleep problems. Additionally, studies show that nicotine replacement can improve sleep quality during withdrawal, which supports the idea that managing sleep can aid in quitting smoking.12345
What safety data exists for sleep management in nicotine addiction treatment?
The safety data for sleep management in nicotine addiction treatment includes the use of dual orexin receptor antagonists (DORAs) like suvorexant and lemborexant, which have a milder adverse event profile compared to previous insomnia treatments. Nicotine replacement therapy has been shown to improve sleep quality post-cessation, despite withdrawal-related sleep disturbances. Studies have also compared the effects of different nicotine patch durations on sleep, indicating that nicotine presence or withdrawal can affect sleep patterns.15678
Is the drug used in the Sleep Management for Nicotine Addiction trial a promising treatment?
Yes, the drug used in the trial, which targets sleep issues with dual orexin receptor antagonists (DORAs), is promising. It helps reduce nicotine cravings and withdrawal difficulties by improving sleep, which is often disturbed during smoking cessation. This approach could make it easier for people to quit smoking and stay smoke-free.13589
Research Team
Karen Cropsey, Psy.D.
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
This trial is for adults over 18 who can read and speak English, identify as non-Hispanic African American or white, and live in Alabama. It's for daily smokers (5+ cigarettes a day for the past year) or non-smokers (less than 100 cigarettes lifetime, none in the last year).Inclusion Criteria
Treatment Details
Interventions
- Sleep extension condition (Behavioural Intervention)
- Sleep restriction condition (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Kierstin Kennedy
University of Alabama at Birmingham
Chief Medical Officer since 2022
MD
S. Dawn Bulgarella
University of Alabama at Birmingham
Chief Executive Officer since 2023
BSc in Commerce and Business Administration from the University of Alabama, MS in Health Administration from the University of Alabama at Birmingham
National Institute on Drug Abuse (NIDA)
Collaborator
Dr. Nora Volkow
National Institute on Drug Abuse (NIDA)
Chief Executive Officer since 2003
MD from National Autonomous University of Mexico
Dr. Nora Volkow
National Institute on Drug Abuse (NIDA)
Chief Medical Officer since 2003
MD from National Autonomous University of Mexico
University of Oklahoma
Collaborator
Dr. Scott Rollins
University of Oklahoma
Chief Executive Officer since 2016
PhD in Immunology from the University of Oklahoma
Dr. Ondria Gleason
University of Oklahoma
Chief Medical Officer
MD from the University of Oklahoma College of Medicine